NPM1 and acute myeloid leukemia: The difference in immune evasion strategies and the resistance of NPM1class II AML cells to allogeneic T cells could explain the difference in survival between the two NPM1 subtypes following HSCT, where NPM1class I responds well whereas NPM1class II AML lacks clinical benefit.